Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Otolaryngology-Head and Neck Surgery, Henry Ford Health System and Henry Ford Cancer Institute, Detroit, Michigan.
Cancer. 2021 Dec 1;127(23):4413-4420. doi: 10.1002/cncr.33773. Epub 2021 Aug 6.
The survival benefit of elective neck dissection (END) for patients with cutaneous squamous cell carcinoma (cSCC) of the head and neck and no evidence of regional metastasis (cN0) has never been reported. The aim of this study was to determine the effect of END on patient survival.
The authors included patients with head and neck cSCC who had undergone primary surgery from 1995 to 2017. The primary end point was survival, and the secondary end points were the incidence of occult regional disease and regional disease control. To assess the impact of END on survival, the authors used multivariable Cox proportional hazards models with propensity score and matching techniques for internal validation.
A total of 1111 patients presented with no evidence of nodal disease; 173 had END, and 938 were observed. Adjuvant radiotherapy to the neck was administered to 101 patients (9%). END resulted in a 5-year overall survival rate of 52%, whereas the rate was 63% in the observation group (P = .003 [log-rank]). The 5-year disease-free survival rate for patients undergoing END was similar to that for the observation group (73% vs 75%; P = .429). A multivariate regression model showed that the performance of END was not associated with improved rates of overall, disease-specific, or disease-free survival; similarly, among patients with advanced disease (T3-4), those who underwent END did not have improved survival rates.
Among patients with cSCC of the head and neck, observation of the neck nodes resulted in noninferior survival rates in comparison with END at the time of primary surgery. Further studies are required to elucidate the role of END in patients with advanced disease.
对于头颈部皮肤鳞状细胞癌(cSCC)且无区域转移证据(cN0)的患者,选择性颈部清扫术(END)的生存获益从未被报道过。本研究旨在确定 END 对患者生存的影响。
本研究纳入了 1995 年至 2017 年间接受头颈部 cSCC 原发手术的患者。主要终点是生存,次要终点是隐匿性区域疾病和区域疾病控制的发生率。为了评估 END 对生存的影响,作者使用了多变量 Cox 比例风险模型、倾向评分匹配技术进行内部验证。
共有 1111 例患者无淋巴结疾病证据;其中 173 例患者接受了 END,938 例患者接受了观察。101 例患者(9%)接受了颈部辅助放疗。END 的 5 年总生存率为 52%,而观察组的生存率为 63%(P=0.003[对数秩检验])。接受 END 的患者 5 年无病生存率与观察组相似(73%比 75%;P=0.429)。多变量回归模型显示,END 的实施与提高总体生存率、疾病特异性生存率或无病生存率无关;同样,在晚期疾病(T3-4)患者中,接受 END 并不能提高生存率。
在头颈部 cSCC 患者中,与原发手术时进行 END 相比,观察颈部淋巴结可获得非劣效的生存率。需要进一步研究以阐明 END 在晚期疾病患者中的作用。